Paracetamol in therapeutic dosages and acute liver injury: Causality assessment in a prospective case series

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Sabaté, Mònica ^a   Ibáñez, Luisa ^a   Pérez, Eulàlia ^a   Vidal, Xavier ^a   Buti, Maria ^b   Xiol, Xavier ^c   Mas, Antoni ^d   Guarner, Carlos ^e   Forné, Montserrat ^f   Solà, Ricard ^g   Castellote, José ^c   Rigau, Joaquim ^h   Laporte, Joan Ramon ^a  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Hospital Universitari Prínceps d'Espanya de Bellvitge   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h Hospital General   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL; ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ARTHRALGIA; ARTICLE; CASE STUDY; CAUSAL ATTRIBUTION; CLINICAL TRIAL; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; EOSINOPHILIA; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERSENSITIVITY REACTION; JAUNDICE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTOPENIA; ACUTE LIVER FAILURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG HYPERSENSITIVITY; LIVER; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; JAUNDICE; LIVER; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; YOUNG ADULT;

EID: 79960564540     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-80     Document Type: Article

References (47)

1. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM, . Acute Liver Failure Study Group Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-72. 10.1002/hep.20948, 16317692, Acute Liver Failure Study Group.
2. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007, 102:1-5.
3. Myers RP, Li B, Shaheen AA. Emergency department visits for acetaminophen overdose: a Canadian population-based epidemiologic study (1997-2002). CJEM 2007, 9:267-74.
4. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008, 47:1401-15.
5. Moling O, Cairon E, Rimenti G, Rizza F, Pristerá R, Mian P. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther 2006, 28:755-60. 10.1016/j.clinthera.2006.05.002, 16861097.
6. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SHB. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-54.
7. Escorsell A, Mas A, de la Mata M, . Spanish Group for the Study of Acute Liver Failure Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007, 13:1389-95. 10.1002/lt.21119, 17370334, Spanish Group for the Study of Acute Liver Failure.
8. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction. Am J Ther 2000, 7:99-114. 10.1097/00045391-200007020-00007, 11319578.
9. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Safety 2005, 28:227-40. 10.2165/00002018-200528030-00004, 15733027.
10. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure?. Pharmacotherapy 2007, 27:1219-30. 10.1592/phco.27.9.1219, 17723075.
11. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 2006, 296:87-93. 10.1001/jama.296.1.87, 16820551.
12. Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forne M, Sola R, Castellote J, Rigau J, Laporte JR. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007, 25:1401-09. 10.1111/j.1365-2036.2007.03338.x, 17539979.
13. Benichou C. Criteria of drug-induced liver disease. Report of International Consensus Meeting. J Hepatol 1990, 11:272-76.
14. Ibáñez L, Pérez E, Vidal X, Laporte JR, . Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB) Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002, 37:592-600. 10.1016/S0168-8278(02)00231-3, 12399224, Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB).
15. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of internal consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-30. 10.1016/0895-4356(93)90101-6, 8229110.
16. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez de la C. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001, 33:123-30. 10.1053/jhep.2001.20645, 11124828.
17. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000, 33:1003-05. 10.1016/S0168-8278(00)80136-1, 11131436.
18. García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ, . Spanish Group for the Study of Drug-induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos) Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008, 27:780-89. 10.1111/j.1365-2036.2008.03655.x, 18284654, Spanish Group for the Study of Drug-induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos).
19. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-36. 10.1016/0895-4356(93)90102-7, 8229111.
20. BOT y Atención Farmacéutica (CD-ROM) Consejo General de Colegios Oficiales de Farmacéuticos. Versión 4. Madrid 2009, 2841555, 21197180, BOT y Atención Farmacéutica.
21. Bromer MQ, Black M. Acetaminophen hepatotoxicity. Clin Liver Dis 2003, 7:351-67. 10.1016/S1089-3261(03)00025-4, 12879988.
22. Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr Opin Gastroenterol 2006, 22:223-33. 10.1097/01.mog.0000218958.40441.fd, 16550036.
23. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep 1999, 1:42-49. 10.1007/s11894-999-0086-3, 10980926.
24. Leeder JS, Pirmohamed M. Anticonvulsant agents. Drug-induced liver disease 2003, 425-46. New York: Marcel Dekker, Kaplowitz N, DeLeve LD.
25. Rumack BH. Acetaminophen misconceptions. Hepatology 2004, 40:10-15.
26. Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what don't we know, and what do we do next?. Hepatology 2004, 40:23-26.
27. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002, 40:3-20. 10.1081/CLT-120002882, 11990202.
28. Holtzman JL. The effect of alcohol on acetaminophen hepatotoxicity. Arch Intern Med 2002, 162:1193. 10.1001/archinte.162.10.1193, 12020193.
29. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients. Arch Intern Med 2001, 161:2247-52. 10.1001/archinte.161.18.2247, 11575982.
30. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of acetaminophen (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007, 26:283-90. 10.1111/j.1365-2036.2007.03368.x, 17593074.
31. Andrade RJ, Lucena MI, García-Escaño MD, Camargo R. Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol 1998, 28:1078-80. 10.1016/S0168-8278(98)80361-9, 9672188.
32. Andrade RJ, Lucena MI, Fernández-Sánchez MC, Peláez G. Hepatotoxicidad por paracetamol a dosis terapéuticas. Med Clin 1997, 109:317-18.
33. Andrade RJ, Lucena MI, Melgarejo F, García-Escaño MD. Hepatotoxicity caused by isoniazid or paracetamol. Gastroenterol Hepatol 1998, 21:314-15.
34. Bolesta S, Haber SL. Hepatotoxicity associated with chronic acetaminophen administration patients without risk factors. Ann Pharmacother 2002, 36:1482-83.
35. Moling O, Cairon E, Rimenti G, Rizza F, Pristerá R, Mian P. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther 2006, 28:755-60. 10.1016/j.clinthera.2006.05.002, 16861097.
36. Kurtovic J, Riordan SM. Acetaminophen-induced hepatotoxicity at recommended dosage. J Intern Med 2003, 253:240-43. 10.1046/j.1365-2796.2003.01097.x, 12542566.
37. Guérin C, Casez JP, Vital-Durand D, Levrat R. Allergy to paracetamol. A case of hepatic and cutaneous involvement. Therapie 1984, 39:47-49.
38. Bacon TH, Hole JG, North M, Burnett I. Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the knee. Br J Clin Pharmacol 2002, 53:629-36. 10.1046/j.1365-2125.2002.01603.x, 1874331, 12047487.
39. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004, 38:S44-S48. 10.1086/381446, 14986274.
40. Boussetta K, Ponvert C, Karila C, Bourgeois ML, Blic J, Scheinmann P. Hypersensitivity reactions to paracetamol in children: a study of 25 cases. Allergy 2005, 60:1174-77. 10.1111/j.1398-9995.2005.00855.x, 16076304.
41. de Paramo BJ, Gancedo SQ, Cuevas M, Camo IP, Martin JA, Cosmes EL. Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol 2000, 85:508-11. 10.1016/S1081-1206(10)62580-X, 11152174.
42. Kvedariene V, Bencherioua AM, Messaad D, Godard P, Bousquet J, Demoly P. The accuracy of the diagnosis of suspected paracetamol (acetaminophen) hypersensitivity: results of a single-blinded trial. Clin Exp Allergy 2002, 32:1366-69. 10.1046/j.1365-2222.2002.01476.x, 12220477.
43. Kenney B, Stack G. Drug-induced Thrombocytopenia. Arch Pathol Lab Med 2009, 133:309-314.
44. Abecia LC, García del Pozo J, de Abajo FJ. Utilización de analgésicos no opioides en España 1992-2006. AGEMED 2009, http://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/analgesicos_no_opio.pdf
45. Lucena MI, García-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008, 22:141-58. 10.1111/j.1472-8206.2008.00566.x, 18353109.
46. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J, . Drug Induced Liver Injury Network (DILIN) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-34. 10.1053/j.gastro.2008.09.011, 18955056, Drug Induced Liver Injury Network (DILIN).
47. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007, 11:477-505. 10.1016/j.cld.2007.06.003, 17723916.